University of Groningen, Groningen Biomolecular Sciences and Biotechnology Institute, Molecular Genetics Group, Kerklaan 30, 9751 NN, Haren, The Netherlands.
Expert Opin Biol Ther. 2011 Mar;11(3):261-7. doi: 10.1517/14712598.2011.542138. Epub 2011 Jan 5.
The use of the lactic acid bacterium Lactococcus lactis, primarily used in food fermentations, as therapeutic agent is no longer speculative but an imminent reality. After the successful completion of Phase I and II clinical trials in humans for the treatment of inflammatory bowel disease, an ongoing clinical trial to alleviate oral mucositis as well as the development of a pneumococcal and a flu vaccine using genetically modified L. lactis, many exciting possibilities exist to develop novel therapeutic and prophylactic biopharmaceuticals to alleviate a wide range of diseases. Here, we discuss existing characteristics of the systems currently employed and the nature of the immune responses evoked. We also discuss the criteria that are fundamental to making the systems feasible and efficient which should ultimately translate into human therapies. Finally, we examine the prospects for L. lactis to become a commercially viable therapeutic agent.
利用乳酸乳球菌（主要用于食品发酵）作为治疗剂已不再是推测，而是迫在眉睫的现实。在成功完成治疗炎症性肠病的 I 期和 II 期临床试验后，目前正在进行临床试验以减轻口腔黏膜炎，以及使用基因修饰的乳酸乳球菌开发肺炎球菌和流感疫苗，这为开发新型治疗和预防生物制药以缓解广泛的疾病提供了许多令人兴奋的可能性。在这里，我们讨论了目前使用的系统的现有特性和引起的免疫反应的性质。我们还讨论了使系统可行和有效的基本标准，这些标准最终应转化为人类治疗方法。最后，我们研究了乳酸乳球菌成为商业可行的治疗剂的前景。
